Test Menu

To order our tests, download and complete the requisition form, then fax form to 615-255-1330.

Contact us to learn more about our upcoming offerings.
 

Available Now

 

Insight ALK Screen

 

 

This highly sensitive qPCR test detects the presence of any of numerous possible fusions in the ALK gene. Tumors with ALK fusions tend to be highly responsive to treatment with kinase-inhibiting drugs such as crizotinib. Results are unambiguous and returned in 24 – 48 hours.

This test is only available through Insight Molecular Labs.

   

KRAS Gene Mutation Analysis

 

KRAS-This test detects mutations commonly found in tumors that tend to be unresponsive to treatment with anti-EGFR drugs such as cetuximab, panitumumab, gefitinib and erlotinib.

   

BRAF Gene Mutation Analysis

  This test detects mutations commonly found in tumors that tend to be responsive to BRAF inhibitors such as Sorafenib and Vemurafenib.

Coming Soon

 

Insight ALK Resistance

  This test is based on highly sensitive qPCR methods and is able to detect and differentiate between 11 mutations that are known to infer varying levels of resistance to targeted kinase inhibitors such as crizotinib.

This test is only available through Insight Molecular Labs.
 
   

Insight ALK ECD

  This qPCR test detects the overexpression of the extra-cellular domain of the ALK protein, which has been linked to various forms of breast cancer.

This test is only available through Insight Molecular Labs.
 
   

EGFR Gene Mutation Analysis

  This test detects the presence of any of 29 different mutations in the tyrosine kinase region of the EGFR gene. These mutations are commonly found in solid tumors especially in lung cancers. Tumors with EGFR mutations tend to respond well to EGFR targeted drugs such as cetuximab, panitumumab, gefitinib and erlotinib.
 
   

Insight Resistance ID

 

This comprehensive Next Generation Sequencing panel will identify the key mechanisms of ALK inhibitor resistance. The detection of the precise inhibitor resistance mechanism(s) driving an individual patient’s tumor will guide physicians in tailoring clinical decisions including second-line therapy or appropriate clinical trials. Samples that have failed QC Analysis will be reported within 48 hours of receipt of material.

This test is only available through Insight Molecular Labs.